Long-term safety of alirocumab versus placebo in high cardiovascular risk hypercholesterolemia

Phase 3, randomised, double-blind trial in hypercholesterolemia and familial hypercholesterolemia (FH) comparing Alirocumab plus background lipid-modifying therapy with Placebo plus background lipid-modifying therapy (2 arms). Primary endpoints: Percent change from baseline in LDL cholesterol at week 24 and Adverse events. Started Feb 2012; status: active, not recruiting.